In this file:

In Issue 2, Study OLS-114 cleared its site initiation visit. Green to enroll, on paper. But a site cannot enroll a study. It can only enroll a person, and Study OLS-114 did not have one yet. That changed the following week, when a neurologist across town mentioned the trial to a patient of his: a retired mail carrier, 64, managing Parkinson's disease for eight years, who was tired of losing entire afternoons to OFF time. We will call him Walter. He is invented, like everything else here, but the visit that follows is not.

Before Walter ever sat down, Nani had already done a first pass. She pulled his chart against the inclusion and exclusion criteria, the same list she had read like a medication order back in Issue 1, twice, because a patient enrolled who should not be is the research version of a wrong dose. Diagnosis and disease duration in range. Age in range. No excluded medications on his current list. Nothing yet that ruled him out. That earned him a screening visit, not a spot on the study. Those are two different things, and mixing them up is one of the most common new-coordinator mistakes.

At the visit itself, the checklist became real: vitals, labs drawn and sent out, an ECG, a structured assessment of his Parkinson's symptoms, a review of every medication and supplement he took, matched line by line against the protocol's exclusion list. Every box on that page is a gate the protocol built on purpose. None of them are there to make the visit longer. They are there because someone, somewhere, decided this study needed to answer its question safely, and that starts with who is allowed to answer it.

Then came the part Nani had been most nervous about: consent.

She had pictured it as a form. Dr. Reyes had corrected her gently at the SIV: consent is a conversation that happens to end with a signature, not the other way around. So Nani sat with Walter for the better part of an hour. She walked him through what the study was asking, what would happen at each visit, the real risks, the real possible benefits, and the one line every consent form is required to say plainly: this is voluntary, and he could leave the study at any time, for any reason, without it changing his care.

Near the end, she tried something Lynn, the pharmacist, had taught her that morning: instead of asking "any questions?" and getting a polite no, she asked Walter to explain the study back to her in his own words. He got most of it right. He missed one thing entirely, that the diary he would fill out at home was not optional homework but one of the ways the study would judge whether the drug was working. She caught it because she asked, not because he raised his hand.

Not every candidate becomes a patient. Later that same week, a second person who had expressed interest turned out to have a lab value just outside the protocol's range. Nani had to tell him he would not be moving forward.

It is a hard call to make well. The script Mira had walked the team through at the SIV was simple and honest: this is not about you as a person, and it is not a judgment. The study has a very specific question to answer, and the criteria exist to protect people for whom this particular drug, at this particular dose, in this particular disease state, might not be safe or might not give a clear answer. He was logged in the screen failure log, the same way Walter was logged in the screening log, both permanent records, because a site's job is to account for everyone who walked through the door, not just the ones who made it onto the study.

By Friday, Walter's consent form was signed, witnessed, and filed. His labs were still pending. Nani could not do anything else until they came back; enrollment was not hers to grant, it belonged to a set of numbers on their way from an outside lab. She spent the afternoon building his source documents anyway, so that if the labs cleared, nothing would be sitting in her way.

That is most of what the job feels like in the gap between a good visit and an actual enrollment: not knowing yet, and getting ready anyway.

Screening is not the same as enrollment, and consent is not the same as a signature. Check every criterion like it is a medication order. Have the patient explain the study back to you before you believe they understood it. And when someone does not qualify, log it plainly and explain it kindly. The list exists to protect the person in front of you, even when it means telling them no.

The Open Site File is general education about how clinical research sites work. It is not regulatory, legal, or medical advice, and it is not tied to any specific study, sponsor, or employer. Study OLS-114, Walter, and all names are invented. Always follow your own site's SOPs, your protocol, and your PI and QA team. Characters are composites.

Filed by Justin Yamashita, MSc., Open Label Media

Next in the file: the enrollment question. Why passing screening is not the finish line, what a randomization system actually decides, and the paperwork that turns "eligible" into "on study."